RE:RE:RE:RE:RE:RE:Theralase Is still Flying Under the RadarScience first, I agree, Dr. Kamat is Primarily a Skilled Urological Surgeon. He does not have to offer a plug on TLD as a viable alternative BCG unresponsive Bladder cancer patients, every chance that he gets. By being on the Medical advisory board, he has access to all the data as and when it is available. He has the knolwedge to interpret whether TLD is a promising treatment in the pipeline. There is nothing that prevents Dr. Kamat from speaking about the Promising treatment and alternative to Bladder removal. On the contrary, he can certainly speak about his views on TLD couple of times a year without appearing to look like a Pumper of penny stocks. I would not be surprised at all, IF TLD was being developed by a major pharma company and he is on the board of let us say Merck or Pfizer, he would be offering his views on it....